Targeting the Microbiome to Overcome Resistance

Baruch, 2020, Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients, Science, eabb5920 Gide, 2018, Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma, Clin. Cancer Res., 24, 1260, 10.1158/1078-0432.CCR-17-2267 Gopalakrishnan, 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, 97, 10.1126/science.aan4236 Jansen, 2019, Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma, Ann. Oncol., 30, 1154, 10.1093/annonc/mdz110 Larkin, 2019, Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma, N. Engl. J. Med., 381, 1535, 10.1056/NEJMoa1910836 Matson, 2018, The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science, 359, 104, 10.1126/science.aao3290 McQuade, 2019, Modulating the microbiome to improve therapeutic response in cancer, Lancet Oncol., 20, e77, 10.1016/S1470-2045(18)30952-5 Robert, 2019, Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study, Lancet Oncol., 20, 1239, 10.1016/S1470-2045(19)30388-2 Routy, 2018, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, 359, 91, 10.1126/science.aan3706 Wang, 2018, Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis, Nat. Med., 24, 1804, 10.1038/s41591-018-0238-9